Ipsen Pharma: Ipsen's Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

Iqirvo® (elafibranor) 80 mg tablets is the first new medicine approved in nearly a decade for the treatment of the rare liver

Related Keywords

Paris ,France General ,France ,Macau ,United States ,China ,United Kingdom ,Washington ,Hong Kong ,Taiwan ,American ,Christelle Huguet ,Rachel Reiff ,Kris Kowdley ,Nicolas Bogler ,Anna Gibbins ,Amy Wolf ,Carol Roberts ,Clin Gastroenterol Hepatol ,Ipsen Euronext ,Ipsen Pharmaceuticals Inc ,Regulatory Agency ,Liver Institute ,Head Of Research ,Drug Administration ,Fibrotic Liver Disease Consortium Investigators ,Ipsen Pharmaceuticals ,Newborn Development ,European Medicines Agency ,Executive Vice President ,New England Journal ,Important Safety Information ,Liver Institute Northwest ,Executive President ,United Kingdom Medicines ,Induced Liver Injury ,Adverse Event ,Reproductive Potential ,Prescribing Information ,Breakthrough Therapy Designation ,Rare Disease ,Sponsored Leveli American Depositary Receipt ,French Autorit ,Des March ,Universal Registration Document ,Primary Biliary ,Liver Disease Consortium ,Increasing Prevalence ,Primary Biliary Cholangitis ,Reduced Mortality With ,Clin Gastroenterol ,Ihr Portfolio ,